CURR - CURE Pharmaceutical Holding Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
3.8000
-0.0800 (-2.06%)
At close: 3:54PM EDT
Stock chart is not supported by your current browser
Previous Close3.8800
Open3.9000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range3.7500 - 3.9500
52 Week Range0.5480 - 4.9000
Volume31,632
Avg. Volume72,293
Market Cap102.788M
Beta (3Y Monthly)4.85
PE Ratio (TTM)N/A
EPS (TTM)-0.4210
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Benzinga10 days ago

    CURE Pharmaceutical Expands DEA License To Manufacture Cannabinoid Molecules

    CURE Pharmaceutical Holding Corp (OTC: CURR ) said Tuesday it managed to broaden its license from the U.S. Drug Enforcement Administration. The expanded license as an authorized manufacturer of Schedule ...

  • GlobeNewswire10 days ago

    CURE Pharmaceutical Expands U.S. DEA Approval to Manufacture Pharmaceuticals Using Whole Cannabis Plant

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has broadened its U.S. Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD). This license allows CURE to take advantage of its latest U.S. Patent No. 10,238,705 issuing this month for the extraction and purification of cannabis plant material, as well as subsequent processing of cannabis extracts for drug formulation. CURE will develop and manufacture cannabis-derived and synthetic cannabidiol-based pharmaceutical products using its CUREfilm™ technology at its facility in Oxnard, Calif.  CUREfilm technology is ideal for the delivery of cannabinoids as it offers increased bioavailability, ease and precision of dosing and greater palatability.

  • GlobeNewswire2 months ago

    National Healthcare Economics and Policy Expert Ruben Jose King-Shaw Jr Joins CURE Pharmaceutical’s Board of Directors

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced Ruben Jose King-Shaw Jr. has joined its Board of Directors. King-Shaw brings significant expertise in healthcare, government and finance. King-Shaw joins the recently named chairman William (Bill) Yuan and Dr. Gene Salkind, expanding the board to six.

  • GlobeNewswire2 months ago

    CURE Pharmaceutical Appoints Chairman, Adds Member to its Board of Directors

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has appointed William (Bill) Yuan to Chairman of the Board and Dr. Gene Salkind to its Board of Directors.

  • GlobeNewswire2 months ago

    CURE Pharmaceutical To Present at Benzinga Cannabis Capital Conference

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it will host an investor presentation at the Benzinga Cannabis Capital Conference at the Eden Roc Miami Beach Hotel in Miami on January 16, 2019 at 5pm. “This conference is the ideal kick-off to 2019, which is set to be a landmark year for the cannabis industry,” said Rob Davidson, CEO of CURE Pharmaceutical. If you would like to schedule a meeting with CURE Pharmaceutical, please contact Ashley Ray at aray@olmsteadwilliams.com.

  • GlobeNewswire4 months ago

    CURE Pharmaceutical Names Veteran Executive as Chief Financial Officer

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has tapped Alex Katz to be the company’s Chief Financial Officer. Bringing his expertise in venture capital, Katz will oversee the company’s financial functions and investment relations. “Our company is approaching 2019 amidst exponential growth and a clear vision to be a leader in drug delivery innovation,” said Robert Davidson, CEO and Chairman of the Board of CURE Pharmaceutical.

  • GlobeNewswire5 months ago

    Prominent Biotech Investor Gene Salkind Adds Another $2M Investment in CURE Pharmaceutical

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, has announced that the company secured a $2 million investment at $2.5 per share from Gene Salkind, a company advisor and biotech investor, bringing his total investment in the company to $3 million. In February 2018, Dr. Salkind joined CURE’s advisory board to help advance CURE’s pipeline for the central nervous system and other therapeutic areas. “This second round of financing from Dr. Salkind is an example of the confidence our investors see in the company’s future,” said Robert Davidson, CEO and Chairman of the Board of CURE Pharmaceutical.